Make DORIBAX® your carbapenem
Review guidelines and clinical data:
- Guidelines from the IDSA and Surgical Infection Society: A-1 recommendation for high-risk cIAI
- For patients with cIAI infections, DORIBAX® has proven clinical efficacy with half the recommended daily dose of meropenem*
- In cIAI patients with severe infection, DORIBAX® has been proven through subset analyses in:
- For patients with cUTI, including pyelonephritis: DORIBAX® has demonstrated excellent clinical cure rates in severe or “high risk” populations
* Based on recommended every 8 hour dosing.
Please see Indications and Important Safety Information below.